Patents Assigned to Academia Sinica
  • A VACCINE COMPRISING A NANOPARTICLE ENCAPSULATING EPITOPES AND ADJUVANT FOR NEUTRALIZING VIRUS INFECTION
    Publication number: 20220218814
    Abstract: We utilized a biocompatible hollow polymeric nanoparticle that coencapsulates T cell epitope peptides and oligodeoxynucleotide (ODN) CpG, and designed immunization strategies to evaluate its protectivity against influenza viruses in mice. This nanoparticle-based peptide vaccine adjuvanted with CpG stimulated robust antigen-specific CD4 and CD5 T cell immunity, but only caused minimal adverse effects compared with crude mixture of peptides and CpG. We used two peptides derived from the nucleocapsid protein (NP), MHC class I-restricted NP366-374 and MHC class ll-restricted NP311-325. This novel nanoparticle vaccine with two epitope peptides plus CpG induced robust and fully protective T cell immunity against influenza viruses.
    Type: Application
    Filed: May 8, 2020
    Publication date: July 14, 2022
    Applicants: ACADEMIA SINICA, NATIONAL TAIWAN UNIVERSITY
    Inventors: Che-Ming Jack HU, Hung-Chih YANG
  • NANOCOMPOSITE AND USES THEREOF
    Publication number: 20220220370
    Abstract: Disclosed herein is a nanocomposite comprising a core-shell nanoparticle and a core-shell quantum dot. The core-shell nanoparticle comprises a phosphor core, a shell layer, and a cleavable peptide. The core-shell quantum dot comprises a center core, an intermediate layer, an outer layer, a silica layer, and an arginylglycylaspartic acid (RGD) peptide. The core-shell nanoparticle and the core-shell quantum dot are linked to each other via forming a peptide bond between the cleavable peptide and the RGD peptide. Also disclosed are the uses of the nanocomposite in making a diagnosis of tumors.
    Type: Application
    Filed: July 29, 2020
    Publication date: July 14, 2022
    Applicant: Academia Sinica
    Inventors: Michael HSIAO, Ming-Hsien CHAN, Subbiramaniyan KUBENDHIRAN, Ming-Che HSIEH, Zhen BAO, An-Bang WANG, Ru-Shi LIU
  • Reloadable hydrogel system for treating brain conditions
    Patent number: 11382983
    Abstract: A drug delivery system and methods of using such for delivering a peglyated therapeutic agent to brain. The drug delivery system may comprise an antibody, which binds polyethylene glycol (PEG), wherein the antibody is embedded in a hydrogel, which may comprises one or more biodegradable polymers, up to 60% of which contain inter-chain or intra-chain covalent crosslinks. The amount of the antibody in the drug delivery system can be about 1-2 ?g per ?l of the hydrogel.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 12, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Patrick C. H. Hsieh, David Lundy, Christopher Yu-Tai Yen
  • METHODS OF TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20220213188
    Abstract: Provided herein is a method for treating neurodegenerative diseases, such as Alzheimer's disease (AD), by use of monoclonal antibody, which exhibits a binding affinity to Siglec-3 receptor. According to some embodiments of the present disclosure, the monoclonal antibody is capable of enhancing phagocytosis of neurotoxic peptides by immune cells thereby providing a neuroprotective effect to a subject in need thereof.
    Type: Application
    Filed: September 25, 2019
    Publication date: July 7, 2022
    Applicant: Academia Sinica
    Inventors: Shie-Liang HSIEH, Pei-Shan SUNG, Ming-Ting HUANG, An-Suei YANG, Chung-Ming YU
  • Methods for modifying human antibodies by glycan engineering
    Patent number: 11377485
    Abstract: Methods for making modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Antibodies comprising Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: July 5, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • CELL CULTURE SUBSTRATES, METHODS AND USES THEREOF
    Publication number: 20220204944
    Abstract: The present disclosure provides a substrate for cell culture. Systems comprising the substrate, and methods for using and manufacturing the substrate are also disclosed herein.
    Type: Application
    Filed: December 30, 2021
    Publication date: June 30, 2022
    Applicant: Academia Sinica
    Inventor: Ying-Chih CHANG
  • CELL CULTURE SYSTEMS, METHODS AND USES THEREOF
    Publication number: 20220204943
    Abstract: The present disclosure provides a surface coating comprising a hydrophilic polymer and polyelectrolyte multilayers. Also provided is a cell culture system comprising a cell culture article having a surface coated with the surface coating. Uses and methods of preparing the surface coatings and systems are provided as well.
    Type: Application
    Filed: December 30, 2021
    Publication date: June 30, 2022
    Applicant: Academia Sinica
    Inventor: Ying-Chih CHANG
  • Bi-specific antibodies and uses thereof
    Patent number: 11369690
    Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: June 28, 2022
    Assignee: ACADEMIA SINICA & KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Steven R Roffler, Tian-Lu Cheng, Chien-Han Kao, Bing-Mae Chen, Yu-Cheng Su, Hsin-Yi Tung, Kuo-Hsiang Chuang
  • ATF3 induction compounds
    Patent number: 11365200
    Abstract: The invention relates to compounds for treating and/or preventing obesity and obesity-related disorders. Particularly, the invention provides chromanone derivatives used as ATF3 inducer and for treating and/or preventing obesity and obesity-related disorders such as heart disease, hypertension, hyperlipidemia and diabetes.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: June 21, 2022
    Assignees: TAIPEI MEDICAL UNIVERSITY, NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE, MINISTRY OF HEALTH AND WELFARE, ACADEMIA SINICA, BUDDHIST TZU CHI MEDICAL FOUNDATION
    Inventors: Heng Lin, Ming-jaw Don, Ching-feng Cheng, Jing-jy Cheng, Wen-shan Li, Hui-chen Ku, Hsiao-fen Li, Hsi-hsien Chen, W J Huang
  • Encapsulated functionalized diamond crystal
    Patent number: 11366119
    Abstract: This invention is a functionalized diamond crystal with high dispersibility in high ionic strength solution and/or with specific targeting ability, which comprise a diamond crystal and a fatty acid layer. The fatty acid layer works a surfactant and provides a specific targeting feature for the diamond crystal. The feature of the surfactant makes the diamond crystal being easily dispersed in biological surrounding (e.g., phosphate saline buffer) and the feature of specific targeting ability provides the diamond crystal with specific recognizing specific targets. This invention allows researchers to use diamond crystal as a marker for specific labelling.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: June 21, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Huan-Cheng Chang, Feng-Jen Hsieh, Yen-Wei Chen
  • Plant defense signaling peptides and applications thereof
    Patent number: 11363822
    Abstract: The present invention is related to a novel plant defense signaling peptide and applications thereof.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: June 21, 2022
    Assignee: Academia Sinica
    Inventors: Yet-Ran Chen, Ying-Lan Chen, Mei-Chun Tseng
  • Peptide-conjugated nanoparticles for targeting, imaging, and treatment of prostate cancer
    Patent number: 11357862
    Abstract: An isolated or a synthetic targeting peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 8 is disclosed. The targeting peptide may be conjugated to a component selected from the group consisting of polymeric micelles, lipoprotein-based drug carriers, nanoparticle drug carriers, a chemotherapeutic agent, a micelle, a liposome, dendrimers, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a prostate cancer cell, a stem cell, and an imaging agent. Also disclosed are a kit for imaging and detecting the presence of prostate cancer cells in vivo or in vitro, and a composition for treating prostate cancer, inhibiting prostate cancer cell growth, inducing prostate cancer cell cytotoxicity, and/or increasing the survival rate in a prostate cancer patient.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: June 14, 2022
    Assignee: Academia Sinica
    Inventors: Han-Chung Wu, Chen-Yun Yeh
  • Nuclear paraspeckle assembly transcript 1 as therapeutic targeting in neurodegeneration
    Patent number: 11357788
    Abstract: The present disclosure provides a method of reducing neurodegeneration and/or TDP43 associated aggregation, comprising knocking down the expression of Nuclear Paraspeckle Assembly Transcript 1 (NEAT1) or LncRNA NEAT1. Also provided are methods for screening a candidate agent that reduces neurodegeneration and/or TDP43 associated aggregation in a cell, treating or preventing a neurodegenerative disorder, delaying or preventing the onset of a neurodegenerative disorder or reducing a risk for developing a neurodegenerative disorder in a subject and determining whether a subject is suffering from, or at a risk of developing a neurodegenerative disorder, comprising measuring the presence of cytoplasmic NEAT1 in a biological sample, wherein the presence is indicative of the risk of developing a neurodegenerative disorder.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: June 14, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Hung-Chih Kuo, Yi-Ying Wu
  • DUAL FUNCTION ELECTRO-OPTICAL SILICON FIELD-EFFECT TRANSISTOR MOLECULAR SENSOR
    Publication number: 20220178873
    Abstract: A field effect transistor (FET)-based bio-sensing system is provided. The system comprises a sensor assembly, a light source, a fluidic pump and an electrical measurement. The sensor assembly comprising an FET chip configured with at least one fluidic channel. Wherein the fluidic channel has an inlet and an outlet, and the fluidic pump is connected to the inlet of the fluidic channel and operable to drive a fluid and/or a specimen of interest through the fluidic channel. Wherein the electrical measurement unit is connected to the sensor assembly to detect a change in the electrical characteristics of the FET chip.
    Type: Application
    Filed: December 6, 2021
    Publication date: June 9, 2022
    Applicants: ACADEMIA SINICA, SILICON-BASED MOLECULAR SENSORING TECHNOLOGY CO., LTD.
    Inventors: ChiiDong CHEN, Pradhana Jati Budhi LAKSANA, Chia-Jung CHU
  • Kit and method for producing induced embryonic neural progenitors
    Patent number: 11339405
    Abstract: Disclosed herein are kits comprising transcription factors for inducing a fibroblast cell into an induced embryonic neural progenitor cell. The induced embryonic neural progenitor cell is then capable of differentiating into an astrocyte, an oligodendrocyte or a neuron. Also disclosed are the uses of the kit as a platform for selecting a drug candidate to treat neurological diseases.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: May 24, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Hung-Chih Kuo, Ching-Yu Chuang, Chan-Hsien Yeh
  • LIPOSOMES AND USES THEREOF
    Publication number: 20220151926
    Abstract: Disclosed herein are novel synthetic polypeptides and uses thereof in the preparation of liposomes. According to embodiments of the present disclosure, the synthetic polypeptide comprises a membrane lytic motif, a masking motif, and a linker configured to link the membrane lytic motif and the masking motif. The linker is cleavable by a stimulus, such as, light, protease, or phosphatase. Once being coupled to a liposome, the exposure to the stimulus cleaves the linker that results in the separation of the masking motif from the membrane lytic motif, which in turn exerts membrane lytic activity on the liposome that leads to the collapse of the intact structure of the liposome, and releases the agent encapsulated in the liposome to the target site. Also disclosed herein are methods of diagnosing or treating a disease in a subject by use of the present liposomes.
    Type: Application
    Filed: January 28, 2022
    Publication date: May 19, 2022
    Applicant: Academia Sinica
    Inventors: Hsien-Ming LEE, Hua-De GAO, Jia-Lin HONG, Chih-Yu KUO, Cheng-Bang JIAN
  • Anti-TNF-alpha glycoantibodies and uses thereof
    Patent number: 11332523
    Abstract: The present disclosure relates to a novel class of anti-TNF? monoclonal antibodies or antigen binding fragments comprising a homogeneous population of anti-TNF? IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-TNF? monoclonal antibodies by Fc glycoengineering. The glycoantibodies of the invention may have improved therapeutic values compared to the corresponding monoclonal antibodies that have not been glycoengineered.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: May 17, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Compounds and methods for treating osteoarthritis
    Patent number: 11332490
    Abstract: Disclosed herein are substrates and/or inhibitors of endo-O-sulfatase 1 (Sulf-1). According to some embodiments, the substrates and/or inhibitors of Sulf-1 are compounds of formula (I) or (II), In formula (I) or (II), n is 2 or 3; X is methylene, O, or N; R1 is —SO3M, or —SO2NH2; R2 is C1-6 alkyl or C1-6 alkylamine; and M is a monovalent cation selected from the group consisting of lithium, sodium, potassium, and ammonium. Also encompasses herein are methods of identifying and treating a subject having or suspected of having osteoarthritis.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: May 17, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Shang-Cheng Hung, Chi-Huey Wong, Ting-Jen Cheng
  • Fucosidase from bacteroides and methods using the same
    Patent number: 11319567
    Abstract: The present disclosure relates to an ?-fucosidase having ?-(1,2), ?-(1,3), ?-(1,4), and ?-(1,6) fucosidase activity. The present disclosure also relates to the compositions comprising the ?-fucosidase, and the methods of producing and using the ?-fucosidase in cleaving ?-(1,2), ?-(1,3), ?-(1,4), and/or ?-(1,6)-linked fucoses in the glycoconjugates.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: May 3, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Tsung-I Tsai
  • extract and uses thereof
    Patent number: 11311592
    Abstract: Disclosed herein is the novel use of use of a Bauhinia spp. extract, which may upregulate neprilysin, induce autophagy, protect neuron from amyloidopathy or tauopathy, and/or promote neurite outgrowth, thus the Bauhinia spp. extract of the present disclosure may be used as a dietary supplement for the prophylaxis or treatment of amyloid related neurodegenerative diseases so as to ameliorate or alleviate symptoms associated with the amyloid related neurodegenerative diseases.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: April 26, 2022
    Assignees: ACADEMIA SINICA, INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Chang-Jen Huang, Rita P.-Y. Chen, Yung-Feng Liao, Bo-Kai Wu, Po-Ting Chen, Hui-Ping Tsai, Yi-Cheng Cheng, Cheng-Li Fang, Hung-Chi Chien, Tien-Soung Tong, Ting-Shou Chen, Shu-Jiau Chiou